Paperplane Therapeutics has successfully raised $1.5 million to develop virtual reality (VR) solutions aimed at treating pain and anxiety, particularly in the dental sector. The Montreal-based company specializes in therapeutic VR applications designed to enhance patient experiences during medical procedures.
The funding round was led by Glen Ventures, with contributions from the Gouvernement du Québec through Investissement Québec and several strategic investors, including CABHI, Cedars-Sinai Intellectual Property Company, Anges Québec, and Aventure Capital.
Pain and anxiety present significant challenges for patients, often resulting in delayed medical care and increased discomfort. Approximately 36% of individuals report anxiety during dental visits, and 12% experience extreme fear related to dental procedures. This leads to patients postponing appointments until pain becomes unavoidable, complicating their treatment.
Paperplane Therapeutics aims to address these issues by transforming dental experiences into more manageable ones through immersive VR technology. Their solutions are designed for patients of all ages, with a focus on pediatric care, helping to reduce anxiety and streamline clinical workflows.
The recent funding will allow Paperplane to expand its reach within the North American dental market and explore opportunities in Europe through a partnership with French company HypnoVR, which holds a CE Mark certification.
This investment marks a pivotal moment in Paperplane’s growth, enabling the company to enhance patient outcomes and improve care delivery. The initiative underscores Quebec’s role in advancing healthcare innovation through technology.
For more information, visit the original article on VentureBeat.